RUBIN PAUL D 4

What Happened
Paul D. Rubin, Chief Medical Officer of BioAge Labs (BIOA), exercised stock option(s) on Feb 2, 2026 to acquire a total of 7,433 shares (5,433 at $4.11 and 2,000 at $6.57), paying $35,470 in exercise costs. The same day he sold all 7,433 shares in an open‑market transaction at $18.75 per share for proceeds of $139,369. (The Form 4 also lists the derivative items converted/ disposed at $0.00, reflecting the option-to-stock conversion.)

Key Details

• Transaction date: 2026-02-02 (Form 4 filed 2026-02-03; appears timely).
• Exercises: 5,433 shares @ $4.11 = $22,330; 2,000 shares @ $6.57 = $13,140; total exercise cost $35,470.
• Sale: 7,433 shares @ $18.75 = $139,369 (open-market sale).
• Net cash before taxes/fees (sale proceeds minus exercise cost): ~$103,899.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes: transaction executed under a Rule 10b5-1 trading plan adopted Nov 5, 2024 (F1); the options were fully vested per award terms (vested as of May 11, 2024, with a monthly 1/48th vesting schedule beginning April 1, 2022) (F2, F3).
• Transaction codes: M = option exercise/conversion; S = sale.

Context
This was effectively a cashless exercise and immediate sale: Rubin exercised vested options and then sold the acquired shares the same day. Sales following option exercises are common and, when done under a 10b5‑1 plan, are pre‑scheduled trades rather than ad‑hoc market timing. The filing does not, in itself, indicate management sentiment about BioAge’s outlook.